← Back to Search

MRI Imaging Techniques for Brain Arteriovenous Malformations

N/A

Waitlist Available

Led By Daniela Iancu, MD

Research Sponsored by Ottawa Hospital Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Brain AVMs previously diagnosed with either CT Angiography, MRI or catheter angiography

mRS <=2

Must not have

Contraindication for contrast: GFR < 60 ml/min, allergy to contrast

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is studying how well endovascular embolization works compared to surgery in treating brain arteriovenous malformations.

Who is the study for?

This trial is for adults over 18 with brain arteriovenous malformations (AVMs) visible on MRI, specifically where the abnormal tangle of arteries measures more than 1 cm. Participants must be able to give informed consent, have a minor or no disability from their condition (mRS <=2), and are scheduled for cerebral catheter angiography. Those with non-MRI compatible implants, severe claustrophobia, kidney issues (GFR < 60 ml/min), or contrast allergies cannot join.

What is being tested?

The study tests advanced MRI techniques like susceptibility-weighted imaging and time-resolved magnetic resonance angiography in patients with brain AVMs. These methods aim to provide detailed images of blood flow in the brain to help plan treatments that prevent bleeding or other neurological symptoms without harming normal brain function.

What are the potential side effects?

Since this trial involves MRI scans which are generally safe and non-invasive, side effects are rare but may include discomfort from lying still during the scan or reactions to contrast agents used if applicable.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My brain AVM was confirmed by a CT, MRI, or catheter angiography.

Select...

I can carry out all my usual duties with minimal help.

Select...

I am scheduled for a special brain scan to check for abnormal blood vessels.

Select...

I am older than 18 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot have contrast due to poor kidney function or an allergy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: MRI perfusion imagingExperimental Treatment1 Intervention

SWAN imaging on the GE 3 T has been attempted but the preliminary evidence suggest that the images are of low resolution and difficult to interpret. Similarly, early experience with TRMRA suggest poor spatial and temporal resolution using the standard "out-of-the-box" protocols. Thus, there is a significant opportunity to improve SWAN and TRMRA, to evaluate the evolution of progressive obliteration of the AVM nidus. Specifically, this is attractive for brain AVMs that are treated with radiosurgery as MRI is required for clinical grounds for treatment planning purposes.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MRI perfusion imaging

2018

N/A

~40

0 / 5Eligibility criteria met